Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.60 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.53 |
| ▸ | CKS1B | P61024 | 2/20 | 0.52 |
| ▸ | SKP1 | P63208 | 2/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16652233 | 0.90 | ACHE (0.60) | ACHEPTPN11GPR119CKS1BSKP1 | |
| SCHEMBL713180 | 0.85 | GPR119 (0.61) | ACHEPTPN11GPR119CKS1BSKP1 | |
| SCHEMBL16652446 | 0.84 | ACHE (0.54) | ACHEPTPN11GPR119CKS1BSKP1 | |
| SCHEMBL16654192 | 0.82 | CKS1B (0.60) | ACHEPTPN11GPR119CKS1BSKP1 | |
| SCHEMBL16653817 | 0.80 | GPR119 (0.61) | ACHEPTPN11GPR119CKS1BSKP1 | |
| SCHEMBL31180958 | 0.78 | GPR119 (0.59) | ACHEPTPN11GPR119CKS1BSKP1 | |
| SCHEMBL12740686 | 0.78 | GPR119 (0.82) | ACHEPTPN11GPR119TLR9TLR7 | |
| SCHEMBL16651989 | 0.78 | PTPN11 (0.53) | ACHEPTPN11GPR119CKS1BSKP1 | |
| SCHEMBL25172068 | 0.77 | GPR119 (0.56) | ACHEPTPN11GPR119CKS1BSKP1 | |
| SCHEMBL16662343 | 0.77 | TAAR1 (0.46) | ACHEPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884861-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-9334263-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2015058129-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057953-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, PRKACA, CKMT1A; CKMT1B | ACHE 3557/4885PTPN11 2949/4885GPR119 113/4885 |
| US-20150111857-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, PRKACA, CKMT1A; CKMT1B | ACHE 3557/4885PTPN11 2949/4885GPR119 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.